Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on May 29, 2020, reporting events occurring on May 28, 2020. Arcus Biosciences, Inc. (RCUS), a Delaware corporation, announced the entry into an underwriting agreement for a public offering of its common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 11,000,000 shares of Common Stock.
- Public Offering Price: $27.50 per share.
- Price to Company: $25.85 per share (after underwriting discounts).
- Net Proceeds (Base): Approximately $283.7 million after estimated offering expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,650,000 additional shares.
- Net Proceeds (With Full Option): Approximately $326.3 million if the option is exercised in full.
- Expected Closing Date: June 2, 2020, subject to customary conditions.
Material Changes
The filing discloses a significant capital raise event. The company is transitioning from its prior capital structure to one bolstered by the anticipated influx of approximately $283.7 million to $326.3 million in cash proceeds. No prior period financial metrics (revenue, profit, or margins) are provided in this specific filing as it focuses solely on the equity offering.
Outlook, Risks, and Contingencies
The offering is contingent upon customary closing conditions. The Underwriting Agreement includes standard representations, warranties, covenants, and indemnification obligations. The transaction is being made pursuant to an effective registration statement on Form S-3 (No. 333-238730). The filing notes that representations were made solely for the benefit of the parties to the agreement and may be subject to limitations and confidential disclosures.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected June 2, 2020).
- Confirm whether the underwriters exercise the 1,650,000 share over-allotment option.
- Review the final prospectus supplement for any changes to the offering price or terms.
- Assess the company's use of proceeds in subsequent filings to understand capital allocation strategy.